The new AcuPulse with MultiMode allows me to be much more efficient in the delivery of both deep and superficial fractional laser treatments, enabling me to quickly deliver both modalities using the same hand piece...
Santa Clara, CA (Vocus/PRWEB) March 31, 2011
Lumenis Ltd., the world's largest medical laser company developing, manufacturing and distributing a broad range of high-end medical lasers and sophisticated energy delivery equipment for surgical, ophthalmic and aesthetic applications, launched the new AcuPulse CO2 laser with MultiMode™ technology, at the 31st Annual Conference of the American Society for Laser Medicine and Surgery (ASLMS) on March 30, 2011.
With the new, patent-pending MultiMode technology, AcuPulse now offers the ability to perform both deep and superficial fractional cosmetic treatments using a single hand piece and with a simple, touch-point selection, thereby reducing treatment set-up and procedure time. The first generation AcuPulse, released in September of 2009, was designed for hospitals, clinics and physicians looking to offer a wide range of cosmetic laser procedures while maintaining the ability to upgrade to full surgical capabilities.
“The new AcuPulse with MultiMode allows me to be much more efficient in the delivery of both deep and superficial fractional laser treatments, enabling me to quickly deliver both modalities using the same hand piece,” said Michael H. Gold, MD, Medical Director, Gold Skin Care Center. “Initial results show a high level of patient satisfaction and efficacy for the treatment of photodamage, dyschromias and scars."
AcuPulse is unique in its ability to support a wide range of aesthetic and surgical specialties, delivering fast treatments with very precise and consistent tissue effects, while an easy-to-use navigation system significantly reduces procedure and inter-department set-up time. MultiMode will be a standard feature on all AcuPulse lasers, while all previously installed AcuPulse systems will receive a complimentary upgrade to enable MultiMode capabilities.
“Lumenis has a long history of innovation,” said Dov Ofer, Chief Executive Officer. “We are pleased to offer yet another technological advancement bringing high levels of patient satisfaction and treatment efficacy, as well as great value to our hospital, clinic and physician partners.”
“With the ability to treat more than 100 FDA-cleared indications, touch screen navigation, and patient-personalized settings, AcuPulse continues to deliver a value-conscious platform that supports Aesthetics, Otolaryngology, Gynecology, Neurosurgery and General Surgery,” said Robert Mann, General Manager Global Aesthetics and Dermatology at Lumenis.
Lumenis, the world's largest medical laser company, is a global developer, manufacturer and distributor of laser and light-based devices for surgical, ophthalmic and aesthetic applications, with more than 800 employees worldwide. Lumenis has 270 registered patents, over 260 FDA clearances, an installed base of over 30,000 systems and a presence in over 100 countries. Lumenis endeavors to bring the finest state of the art technology products to the market, fulfilling the highest standards of excellence, quality and reliability, delivering premium value and service to its customers. The name Lumenis is derived from the Latin words meaning "Light of Life" highlighting the light, which is the basis of our technologies, used to enhance life. For more information about Lumenis and its products, please visit: http://www.lumenis.com.
For further information contact:
Director of Corporate Communications